Data from EMC - Curated by Toby Galbraith - Last updated 11 July 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure


IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis


Related Content

More information

Category Value
Agency product number EMEA/H/C/003932
Orphan designation No
Date First Approved 18-02-2016
Type Medicinal product subject to medical prescription
Marketing authorisation holder Grünenthal GmbH